What was the primary driver of revenue growth in the first half of 2017?

Revenue growth was primarily driven by increased sales of Zoetis's dermatology portfolio and new product launches, contributing approximately 6% to operational revenue growth. Growth in in-line products also contributed positively.

How did the company's restructuring and efficiency initiatives impact financial results?

The comprehensive operational efficiency program is substantially complete, leading to a significant decrease in restructuring charges and acquisition-related costs. For the six months ended July 2, 2017, these costs were minimal ($1 million reversal) compared to $19 million in the prior year, reflecting successful cost management and optimization efforts.

What is the company's cash flow situation?

Zoetis demonstrated strong operating cash flow generation, with net cash provided by operating activities increasing by 59% to $299 million for the six months ended July 2, 2017, compared to $188 million in the prior year. This indicates a healthy ability to generate cash from its core operations.

How is Zoetis managing its debt and capital structure?

As of July 2, 2017, Zoetis had $3.7 billion in long-term debt. The company has a $1.0 billion revolving credit facility and had $100 million in commercial paper borrowings outstanding. The company was in compliance with its financial covenants and had access to significant liquidity through its credit facilities and cash on hand.

ZTS 10-Q Quarterly Report Q3 FY2017 — Revenue, Net Income, EPS

Summary

Zoetis Inc. reported solid financial results for the six months ended July 2, 2017. Revenue increased by 5% to $2.5 billion, driven by operational growth in both livestock and companion animal segments. Net income attributable to Zoetis Inc. saw a significant increase of 13% to $485 million for the same period. This growth was supported by strong performance in key product categories, despite some headwinds from product rationalizations and foreign exchange fluctuations. Key financial strategies and operational efficiencies are evident. The company continues to manage its cost structure effectively, with Selling, General, and Administrative (SG&A) expenses decreasing by 2% for the six-month period. Restructuring charges were minimal as the operational efficiency program is substantially complete. Zoetis also demonstrated strong cash flow generation, with net cash provided by operating activities increasing substantially to $299 million for the first six months of the year. The company maintained a healthy liquidity position and continued its commitment to shareholder returns through its share repurchase program.

Financial Highlights

53 data points

Beta

Revenue

$1.27B

0.7% Gross Margin

Net Income

$247.00M

0.2% Net Margin

EPS (Diluted)

$0.50

Total Assets

$7.80B

Cash & Equivalents

$705.00M

Free Cash Flow

$129.00M

Financial Statements

Beta

Revenue	$1.27B
Cost of Revenue	$440.00M
Gross Profit	$829.00M
SG&A Expenses	$336.00M
Operating Expenses	$924.00M
Interest Expense	$41.00M
Net Income	$247.00M
EPS (Basic)	$0.50
EPS (Diluted)	$0.50
Shares Outstanding (Basic)	490.80M
Shares Outstanding (Diluted)	494.00M

Key Highlights

1Revenue increased by 5% to $2.5 billion for the first six months of 2017 compared to the same period in 2016.
2Net income attributable to Zoetis Inc. grew by 13% to $485 million for the first six months of 2017.
3Operating cash flow significantly improved, reaching $299 million for the first six months of 2017, up from $188 million in the prior year.
4Selling, General, and Administrative (SG&A) expenses decreased by 2% for the six-month period, indicating effective cost management.
5The operational efficiency program is substantially complete, resulting in minimal restructuring charges.
6Zoetis continued to return value to shareholders, with approximately $1.3 billion remaining under its share repurchase program as of July 2, 2017.
7Both U.S. and International segments reported revenue growth, with companion animal products showing particular strength.

Zoetis Inc. Quarterly Report for Q3 Ended Jul 2, 2017

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions